Rajiv Sarman Shukla
Director Ejecutivo en CARMELL CORPORATION .
Fortuna: 14 M $ al 31/05/2024
Relaciones activas
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| David Anderson | M | 71 | - | |
| Max Wallace | M | 72 | 3 años | |
| Charles Green | M | 68 | 2 años | |
| Emery Brown | M | 67 | 3 años | |
| Kathleen Sebelius | F | 75 | 3 años | |
| Scott Frisch | M | - | 1 años | |
| Diane Seimetz | M | 53 | 2 años | |
| Michael Constantino | M | 61 | 3 años | |
| Todd Pope | M | 58 | 3 años | |
| Susan Windham-Bannister | M | 74 | 3 años | |
| Kathryn Gregory | F | 62 | - | |
| Colin Richard Green | M | 80 |
InflammX Therapeutics, Inc.
 InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
| Brian Levy | M | 72 |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
| Richard Upton | M | 60 | - | |
| Gilles Spenlehauer | M | - | 1 años | |
| Dale Sander | M | 64 | 3 años | |
| David Alan Pool | M | - |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
| Richard Rubino | M | 66 |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
| James Blair | M | 84 |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
| Suneet Varma | M | 55 | 23 años | |
| Heather Prichard | M | 46 | 3 años | |
| Jason Werner | M | 46 |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
| Phil Rosenfeld | M | - |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
| William Scheessele | M | 53 | 3 años | |
| Mike McDermott | M | 58 | 21 años | |
| Shamik Parikh | M | 51 | 2 años | |
| David Boyer | M | - |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
| Brady Dougan | M | 64 | 3 años | |
| Yang Cao | M | 58 | 2 años | |
| Bryan Cassaday | M | 56 | 1 años | |
| Patrick Sturgeon | M | 47 | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Jeffrey Kindler | M | 68 | 8 años | |
| Alexander John Joseph | M | 85 |
Constellation Alpha Capital Corp.
 Constellation Alpha Capital Corp. Financial ConglomeratesFinance Constellation Alpha Capital Corp. is a blank check company, which engages in the in a share exchange, share reconstruction, amalgamation, acquisition, and business combination with businesses or entities. The company was founded by Rajiv Sarman Shukla on July 31, 2015 and is headquartered in West Palm Beach, FL. | 2 años |
| Craig Pollak | M | 53 |
Constellation Alpha Capital Corp.
Constellation Alpha Capital Corp. Financial ConglomeratesFinance Constellation Alpha Capital Corp. is a blank check company, which engages in the in a share exchange, share reconstruction, amalgamation, acquisition, and business combination with businesses or entities. The company was founded by Rajiv Sarman Shukla on July 31, 2015 and is headquartered in West Palm Beach, FL. | - |
| Michael R. Jirousek | M | 65 | 5 años | |
| Jacob M. Plotsker | M | 56 | 16 años | |
| Paul Fitzhenry | M | 64 | 4 años | |
| David Paul Rasquinha | M | 59 | 3 años | |
| Venkiteswaran Subramaniam | M | 83 | 6 años | |
| Everett Cunningham | M | 57 | 9 años | |
| Jeffrey Lawson | M | 60 | - | |
| Alexandra Kropotova | M | 51 | 5 años | |
| Yi Ning Zhao | M | 53 | 8 años | |
| Richard Rosling | M | 61 |
Constellation Alpha Capital Corp.
Constellation Alpha Capital Corp. Financial ConglomeratesFinance Constellation Alpha Capital Corp. is a blank check company, which engages in the in a share exchange, share reconstruction, amalgamation, acquisition, and business combination with businesses or entities. The company was founded by Rajiv Sarman Shukla on July 31, 2015 and is headquartered in West Palm Beach, FL. | - |
| Nils Peter Sandehed | M | 72 | 1 años | |
| George Milne | M | 80 | 32 años | |
| Padmaja Bhaskaran | F | - | 3 años | |
| Ajay Kumar Parduman Sharma | M | 61 | 1 años | |
| Gordon Binder | M | 88 | 3 años | |
| Comal Ramachandran Gayathri | F | 75 | 4 años | |
| Kewal Kundanlal Handa | M | 71 |
Constellation Alpha Capital Corp.
Constellation Alpha Capital Corp. Financial ConglomeratesFinance Constellation Alpha Capital Corp. is a blank check company, which engages in the in a share exchange, share reconstruction, amalgamation, acquisition, and business combination with businesses or entities. The company was founded by Rajiv Sarman Shukla on July 31, 2015 and is headquartered in West Palm Beach, FL. | - |
| Viviane Monges | F | 60 | 5 años | |
| Mark J. Bamberger | M | 71 | 4 años | |
| Dario Paggiarino | M | 67 | 10 años | |
| Charles Baum | M | 65 | 9 años | |
| Michael Bruce | M | - | 12 años | |
| Caleb DesRosiers | M | 51 | 2 años | |
| John Chapman | M | 70 | 4 años | |
| Feng Guo | M | 54 | 11 años | |
| William S. Korinek | M | - | 9 años | |
| Jeffrey Kent | M | 62 | 4 años | |
| Spiros Liras | M | - | 4 años | |
| Deborah Baron | F | 55 | - | |
| Margaret Marshall | M | 67 | 8 años | |
| Mark J. Taisey | M | - | 5 años | |
| Adrian Otte | M | - | 6 años | |
| Tanya de Foras | F | 53 | 10 años | |
| Tod Smeal | M | 59 | 12 años | |
| Michelle Nasir | F | - | 6 años | |
| Christopher Verni | M | 49 | 3 años | |
| Mariano García-Valiño | M | 58 | 8 años | |
| Paul E. Kirincic | M | 73 | 3 años | |
| Alexander Fowkes | M | - | 5 años | |
| Frank Sciavolino | M | 83 | 35 años | |
| John W. Poyhonen | M | 64 | 7 años | |
| Robert E. Grasty | M | 55 | - | |
| Lance Berman | M | 53 | 6 años | |
| Kenneth Bahrt | M | 71 | 4 años | |
| Stanley O. Ikenberry | M | 88 | 2 años | |
| John F. Niblack | M | 85 | 35 años | |
| Jean-Paul Vallès | M | - | 25 años | |
| William Sigmund | M | - | 4 años | |
| Linda Armstrong | M | 61 | 6 años | |
| Wesley W. Day | M | 59 | 12 años | |
| Warren R. Winter | M | - | 15 años | |
| Julie A. Olson | M | - | 19 años | |
| Joseph Monahan | M | 69 | 7 años | |
| George W. Evans | M | 70 | 26 años | |
| Tim Bertram | M | 68 | 5 años | |
| Charles McWherter | M | 69 | 4 años | |
| Thomas G. Gant | M | - | 6 años | |
| Andreas Fibig | M | 62 | 2 años | |
| Scott Cheshareck | M | - | 16 años | |
| Dan Garofalo | M | 48 | 4 años | |
| Krishan K. Arora | M | 83 | 5 años | |
| Edmund Harrigan | M | 71 | 12 años | |
| Barbara Wirostko | M | 58 | 4 años | |
| Antony Loebel | M | 64 | 1 años | |
| Ravi Kiron | M | 64 | 13 años | |
| Seth Brodsky | M | - | 3 años |
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Estados Unidos | 83 | 83.00% |
| India | 7 | 7.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Rajiv Sarman Shukla
- Red Personal
